亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Use Of Perillyl Alcohol In Organ Transplantation

詳細技術說明: Utilizing both these immunosuppressive mechanisms, UCLA scientists have determined that perillyl alcohol, a widely-known anti-carcinogen, can be used to reduce graft rejection. By inhibiting activation of the p2l ras oncogene, perillyl alcohol blocks activation of the pathway necessary for lymphocyte proliferation and thus activation. In addition, perillyl alcohol can also reduce the side effects of current anti-rejection agents. By working in a pathway different from its counterparts, perillyl alcohol can be administered alone or in conjunction with other immunosuppressive drugs. Therefore, the doses of these established drugs are decreased and the overall side effects are reduced.These findings suggest that perillyl alcohol may be an important mediator in the field of transplantation surgery by preventing acute and chronic graft rejection. Furthermore, its well-documented anti-carcinogenic and anti-microbial properties may prove to be highly beneficial to immunocompromised transplant patients.

*Abstract: Current state of the art in the field of organ transplantation employs various immunosuppressive agents to prevent post-surgical allograft rejection by the host. However, these pharmacological agents often result in many adverse side effects due to the quantities of medication that are required following transplantation. Cyclosporins, tacrilomus, mycophenclate mofetil and rapamycin are among the drugs commonly used today.
The efficacy of these drugs can be attributed to their ability to act as immunosuppressive agents, whereby inhibiting the lymphocyte activation pathway. In turn, the transplanted tissue is not subject to the deleterious effects of the host immune response.
Cytotoxic agents may also be utilized in immunosuppression. Upon antigenic activation, lymphocytes rapidly proliferate as part of the immune response. Cytotoxic agents kill rapidly dividing cells, such as lymphocytes and therefore inhibit activation.

*Principal Investigation: Name: David Imagawa
Department:

Name: Ming Sing Si
Department:

附加資料: Patent Number: US6133324A
Application Number: US1999305997A
Inventor: Imagawa, David K. | Ming Sing, Si
Priority Date: 7 May 1998
Priority Number: US6133324A
Application Date: 6 May 1999
Publication Date: 17 Oct 2000
IPC Current: A61K0031045 | A61K003813 | A61K004506
US Class: 514729 | 5140166 | 5140205 | 5140211 | 514529 | 514011 | 514019
Assignee Applicant: The Regents of the University of California
Title: Use of perillyl alcohol in organ transplantation
Usefulness: Use of perillyl alcohol in organ transplantation
Summary: To prevent allograft rejection (claimed).
Novelty: Perillyl alcohol and its derivatives are used as immunosuppressive agents in organ transplants to reduce rejection

欲了解更多信息，請點擊這裡